From a safety perspective, the mean cumulative monthly doses of IIM administered to the patients in this study to maintain a stable Hb are below IV iron dose levels of ≥200 or ≥ 300 mg per month that have been found in recent long-term (1–2 years) epidemiological studies to be associated with an increased risk of morbidity and mortality in HD patients [24, 25]. Here, GSTM1 is linked to Huntington disease.